DND Pharmatech Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:14
Aug 07
Aug 07
Biotech stocks top pick for H2.
Korean biotech and pharmaceutical stocks are the top sector pick for the second half. Samsung Biologics and Celltrion are stable, large-cap options; Alteogen offers higher growth and volatility; DND Pharmatech presents a buying opportunity after a recent plunge that was not a real negative; Hanall Biopharma is a KOSPI-listed biotech worth watching. The sector benefits from rotation away from overbought semiconductors and from a market environment where many oversold names rebound.
HIGH
02:41
Jun 24
Jun 24
Deal potential and institutional buying.
DND Pharmatech has deal potential and institutional buying support. The active momentum is still valid, making it a name to watch/play within the biotech catalyst theme.
LOW
11:00
Jun 19
Jun 19
Biotech leaders DND Pharmatech, Hanall Biopharma
Within biotech, DND Pharmatech is showing strong relative performance and could become the sector leader. Hanall Biopharma, listed on KOSPI, is already forming a proper uptrend. Watching these early leaders makes sense in a market where only the strongest stocks are working.
LOW
12:30
Jun 17
Jun 17
DND MASH drug licensing deal imminent
DND Pharmatech’s MASH (metabolic dysfunction-associated steatohepatitis) treatment candidate DD01 showed very strong efficacy at 24 weeks and 36 weeks in an ongoing 48-week trial. The CEO indicated they are in licensing negotiations with Big Pharma and could secure a deal worth 2 to 4 trillion won. The stock has been beaten down but is now breaking out with potential for further upside as the deal materializes.
HIGH
11:00
Jun 17
Jun 17
Imminent technology export, top biotech pick.
DND Pharmatech is his top biotech pick. He expects the company to achieve a technology export deal in the near future, with repeated signals of an imminent deal.
MED
00:25
Feb 12
Feb 12
Korean biotech picks still attractive
Alteogen, ABL Bio, and DND Pharmatech still look good.
MED
03:23
Jan 29
Jan 29
Obesity drugs are consumer trend.
Obesity is becoming a consumer trend; Novo Nordisk still has significant upside because oral obesity drugs should see huge demand and remove injection barriers; in Korea he likes DND Pharmatech.
MED
About DND Pharmatech Investor Commentary
Across the available history and selected sources, Buzzberg tracks DND Pharmatech across 2 sources: 7 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 7 total trade ideas tracked. Latest voices: Lee Jae-kyu, Park Ji-eun, Lee Kwon-hee.